These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 11192144

  • 1. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.
    Rothner AD, Winner P, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M.
    Clin Ther; 2000 Dec; 22(12):1533-46. PubMed ID: 11192144
    [Abstract] [Full Text] [Related]

  • 2. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine.
    Natarajan S, Jabbour JT, Webster CJ, Richardson MS.
    Headache; 2004 Dec; 44(10):969-77. PubMed ID: 15546259
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
    Winner P, Rothner AD, Saper J, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M.
    Pediatrics; 2000 Nov; 106(5):989-97. PubMed ID: 11061765
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M.
    CNS Drugs; 2003 Nov; 17(9):653-67. PubMed ID: 12828501
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
    Munjal S, Brand-Schieber E, Allenby K, Spierings ELH, Cady RK, Rapoport AM.
    J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.
    McDonald SA, Hershey AD, Pearlman E, Lewis D, Winner PK, Rothner D, Linder SL, Runken MC, Richard NE, Derosier FJ.
    Headache; 2011 Oct; 51(9):1374-87. PubMed ID: 21797863
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
    Göbel H, Winter P, Boswell D, Crisp A, Becker W, Hauge T, Mihout B, Niewold J, Tørring J.
    Clin Ther; 2000 Aug; 22(8):981-9. PubMed ID: 10972634
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD, Dahlöf CG, Brandes JL, Agosti R, Jones MW, Barrett PS.
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [Abstract] [Full Text] [Related]

  • 19. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
    Winner P, Landy S, Richardson M, Ames M.
    Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.